CARDIFF ONCOLOGY, INC. Selling and Marketing Expense
CARDIFF ONCOLOGY, INC. (CRDF) reported Selling and Marketing Expense of $2.74 million for the 12-month period ending 2017-12-31, per its 10-K filed 2018-02-26.
Discontinued › Expense Statement › Operating Expenses
us-gaap:SellingAndMarketingExpense · last filed 2018-02-26
- CARDIFF ONCOLOGY, INC. selling and marketing expense for the quarter ending 2017-12-31 was $292.48K, a 87.79% decline year-over-year.
- CARDIFF ONCOLOGY, INC. selling and marketing expense for the quarter ending 2017-09-30 was $419.93K, a 85.72% decline year-over-year.
- CARDIFF ONCOLOGY, INC. selling and marketing expense for the quarter ending 2017-06-30 was $615.02K, a 80.34% decline year-over-year.
- CARDIFF ONCOLOGY, INC. selling and marketing expense for the quarter ending 2017-03-31 was $1.41M, a 53.95% decline year-over-year.
- CARDIFF ONCOLOGY, INC. selling and marketing expense for fiscal 2017 was $2.74M, a 76.26% decline from fiscal 2016.
- CARDIFF ONCOLOGY, INC. selling and marketing expense for fiscal 2016 was $11.52M, a 78.83% increase from fiscal 2015.
- CARDIFF ONCOLOGY, INC. selling and marketing expense for fiscal 2015 was $6.44M, a 135.61% increase from fiscal 2014.
- CARDIFF ONCOLOGY, INC. selling and marketing expense for fiscal 2014 was $2.73M, a 78.73% increase from fiscal 2013.
| Period end | Selling and Marketing Expense 3 month | Selling and Marketing Expense 6 month | Selling and Marketing Expense 9 month | Selling and Marketing Expense 12 month | Selling and Marketing Expense 176 month |
|---|---|---|---|---|---|
| 2017-12-31 | $292.48K derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-26 | $712.41K derived: sum of 2 quarters · filed 2018-02-26 | $1.33M derived: sum of 3 quarters · filed 2018-02-26 | $2.74M 10-K · filed 2018-02-26 | |
| 2017-09-30 | $419.93K 10-Q · filed 2017-11-09 | $1.03M derived: sum of 2 quarters · filed 2017-11-09 | $2.44M 10-Q · filed 2017-11-09 | $4.84M derived: sum of 4 quarters · filed 2018-02-26 | |
| 2017-06-30 | $615.02K 10-Q · filed 2017-08-09 | $2.02M 10-Q · filed 2017-08-09 | $4.42M derived: sum of 3 quarters · filed 2018-02-26 | $7.36M derived: sum of 4 quarters · filed 2018-02-26 | |
| 2017-03-31 | $1.41M 10-Q · filed 2017-05-10 | $3.80M derived: sum of 2 quarters · filed 2018-02-26 | $6.74M derived: sum of 3 quarters · filed 2018-02-26 | $9.87M derived: sum of 4 quarters · filed 2018-02-26 | |
| 2016-12-31 | $2.40M derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-26 | $5.34M derived: sum of 2 quarters · filed 2018-02-26 | $8.47M derived: sum of 3 quarters · filed 2018-02-26 | $11.52M 10-K · filed 2018-02-26 | |
| 2016-09-30 | $2.94M 10-Q · filed 2017-11-09 | $6.07M derived: sum of 2 quarters · filed 2017-11-09 | $9.13M 10-Q · filed 2017-11-09 | $11.06M derived: sum of 4 quarters · filed 2017-11-09 | |
| 2016-06-30 | $3.13M 10-Q · filed 2017-08-09 | $6.19M 10-Q · filed 2017-08-09 | $8.12M derived: sum of 3 quarters · filed 2017-08-09 | $9.92M derived: sum of 4 quarters · filed 2017-08-09 | |
| 2016-03-31 | $3.06M 10-Q · filed 2017-05-10 | $4.99M derived: sum of 2 quarters · filed 2017-05-10 | $6.79M derived: sum of 3 quarters · filed 2017-05-10 | $8.71M derived: sum of 4 quarters · filed 2017-05-10 | |
| 2015-12-31 | $1.93M derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-15 | $3.73M derived: sum of 2 quarters · filed 2017-03-15 | $5.65M derived: sum of 3 quarters · filed 2017-03-15 | $6.44M 10-K · filed 2017-03-15 | |
| 2015-09-30 | $1.80M 10-Q · filed 2016-11-09 | $3.71M derived: sum of 2 quarters · filed 2016-11-09 | $4.51M 10-Q · filed 2016-11-09 | $5.54M derived: sum of 4 quarters · filed 2017-03-15 | |
| 2015-06-30 | $1.92M 10-Q · filed 2016-08-04 | $2.71M 10-Q · filed 2016-08-04 | $3.75M derived: sum of 3 quarters · filed 2017-03-15 | $4.29M derived: sum of 4 quarters · filed 2017-03-15 | |
| 2015-03-31 | $794.65K 10-Q · filed 2016-05-10 | $1.83M derived: sum of 2 quarters · filed 2017-03-15 | $2.37M derived: sum of 3 quarters · filed 2017-03-15 | $2.96M derived: sum of 4 quarters · filed 2017-03-15 | |
| 2014-12-31 | $1.03M derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-15 | $1.58M derived: sum of 2 quarters · filed 2017-03-15 | $2.17M derived: sum of 3 quarters · filed 2017-03-15 | $2.73M 10-K · filed 2017-03-15 | |
| 2014-09-30 | $540.58K 10-Q · filed 2015-11-09 | $1.13M derived: sum of 2 quarters · filed 2015-11-09 | $1.70M 10-Q · filed 2015-11-09 | $2.07M derived: sum of 4 quarters · filed 2016-03-10 | |
| 2014-06-30 | $589.81K 10-Q · filed 2015-08-10 | $1.16M 10-Q · filed 2015-08-10 | $1.53M derived: sum of 3 quarters · filed 2016-03-10 | $1.86M derived: sum of 4 quarters · filed 2016-03-10 | |
| 2014-03-31 | $569.59K 10-Q · filed 2015-05-05 | $943.59K derived: sum of 2 quarters · filed 2016-03-10 | $1.27M derived: sum of 3 quarters · filed 2016-03-10 | $1.74M derived: sum of 4 quarters · filed 2016-03-10 | $2.61M 10-Q · filed 2014-05-12 |
| 2013-12-31 | $374.00K derived: 10-K 12 month − 10-Q 9 month · filed 2016-03-10 | $704.53K derived: sum of 2 quarters · filed 2016-03-10 | $1.17M derived: sum of 3 quarters · filed 2016-03-10 | $1.53M 10-K · filed 2016-03-10 | |
| 2013-09-30 | $330.52K 10-Q · filed 2014-11-06 | $795.70K derived: sum of 2 quarters · filed 2014-11-06 | $1.16M 10-Q · filed 2014-11-06 | ||
| 2013-06-30 | $465.17K 10-Q · filed 2014-08-07 | $825.63K 10-Q · filed 2014-08-07 | |||
| 2013-03-31 | $360.46K 10-Q · filed 2014-05-12 | ||||
| 2012-12-31 | $506.54K 10-K · filed 2015-03-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Black Diamond Therapeutics, Inc. (BDTX) | United States | $0.109B | -2.48 |
| COGNITION THERAPEUTICS INC (CGTX) | United States | $0.090B | -6.52 |
| Pelthos Therapeutics Inc. (PTHS) | United States | $0.086B | -1.20 |
| Atara Biotherapeutics, Inc. (ATRA) | United States | $0.086B | -6.48 |
| LENZ Therapeutics, Inc. (LENZ) | United States | $0.117B | -1.41 |
| Vaxart, Inc. (VXRT) | United States | $0.080B | 3.84 |
| enGene Therapeutics Inc. (ENGN) | $0.129B | -0.92 | |
| Kalaris Therapeutics, Inc. (KLRS) | United States | $0.073B | -2.19 |
| Neumora Therapeutics, Inc. (NMRA) | United States | $0.132B | -1.48 |
| Armata Pharmaceuticals, Inc. (ARMP) | United States | $0.132B |